Dr Reddy's Laboratories reported a 69% drop in net profit for the June quarter as North American revenue fell by 35%. The decline was largely driven by lower sales of the cancer drug lenalidomide and rising production costs. Investors are now focused on whether the company can recover margins through its Indian market growth and upcoming product launches.
Detailed Coverage
Dr Reddy's Laboratories has reported a difficult start to the current fiscal year, with its June quarter performance missing analyst estimates across key metrics. The company’s total revenue for the period fell by 6% compared to the same time last year. More significantly, net profit saw a sharp 69% decline, while operating profit dropped by 56%. This performance reflects a challenging period for the pharmaceutical major, particularly in its largest international market.
North America Business Faces Major Headwinds
The most significant pressure point for the company was its North American division, which saw revenue contract by 35% year-on-year. This decline was primarily caused by lower sales of lenalidomide, a generic cancer drug that has faced intense competition and pricing pressure. In addition to the loss of exclusivity for this drug, the company also reported weaker sales in its nicotine replacement therapy business, which it attributed to temporary changes in distributor rebates and discounts. Some market analysts have pointed out that the company's core US business has struggled to grow significantly over the past four years, highlighting a need for a more consistent pipeline of complex, high-value generic products.
Profitability and Manufacturing Challenges
Beyond lower revenue, the company’s profit margins were hit by rising costs. The gross margin fell by 750 basis points to 49.4%, while the operating profit margin dropped to 13.5%. These declines were caused by a mix of pricing pressure in the US and Europe, higher costs for raw materials like solvents, and increased freight expenses linked to ongoing geopolitical tensions in the Middle East. Furthermore, recent manufacturing observations from the US Food and Drug Administration (USFDA) at some of the company’s facilities have added uncertainty to the timeline for launching new products, including the arthritis drug abatacept. Disruptions in the manufacturing of semaglutide have also caused analysts to lower their near-term earnings expectations.
Domestic Growth Provides a Buffer
Despite global struggles, the company’s India business remains a strong point. Sales in the domestic market grew by 17% year-on-year, comfortably outpacing the general pharmaceutical sector. This growth was supported by the launch of seven new brands and strong performance from its cancer portfolio, including the drug toripalimab. The company’s ability to leverage its domestic innovation franchise and implement price increases has helped keep the Indian operations on a growth trajectory of over 10%.
Looking ahead, investors will be monitoring the company's progress on resolving manufacturing issues and the actual launch timelines for its pipeline of complex drugs. The ability of the management to control operating expenses and stabilize margins amidst global cost pressures will be key factors for the stock in the coming quarters.